National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) - conditions (No. PB 32 of 2010)

Overview

The National Health Act 1953, as amended by the F2010L00775 instrument, serves as the foundation for the Pharmaceutical Benefits Scheme (PBS), enabling the Commonwealth to ensure Australians have dependable, timely, and affordable access to a broad spectrum of medications. This Act allows the Minister for Health to determine the forms of listed drugs, including their type of unit, which dictates the pharmaceutical benefits provided under the Act. In an effort to rectify an administrative oversight, the F2010L00775 instrument amends an earlier legislative instrument, PB 20 of 2010, to correct the description of the type of unit for the listed drug dabigatran etexilate, changing it from “tablets” to “capsules.” This amendment was made to ensure that the conditions under which payments are made for the supply of pharmaceutical benefits by approved pharmacists and medical practitioners are accurate and in line with the actual form of the drug supplied. The instrument, which was created to address the oversight, was registered on the Federal Register of Legislative Instruments on 26 March 2010 and is intended to take effect before the commencement of PB 20 of 2010 on 1 April 2010.

Scope and Application

The National Health Act 1953, as amended, applies to the Pharmaceutical Benefits Scheme (PBS), which is designed to ensure Australians have access to a wide range of affordable medicines. The Act applies to approved pharmacists and medical practitioners who supply pharmaceutical benefits, which are listed drugs declared by the Minister, including their form, manner of administration, and brand. The Act provides the legislative framework for determining the conditions under which payments are made for these benefits. The Minister can amend the conditions of supply through subordinate instruments, such as PB 20 of 2010, which was corrected by PB 32 of 2010 to accurately reflect the correct form of the drug dabigatran etexilate as capsules rather than tablets. This correction is necessary to ensure the integrity of payments administered by Medicare Australia for the supply of these pharmaceutical benefits. The geographic reach of the Act is national, as it governs the supply of pharmaceutical benefits across Australia through the PBS. There are no stated exclusions or thresholds in the Act as it pertains to the supply of pharmaceutical benefits, although specific exclusions may be found in the subordinate instruments.

Key Provisions

The National Health Act 1953 (the Act) establishes the framework for the Pharmaceutical Benefits Scheme (PBS), which ensures that Australians have access to affordable and reliable medications. Section 85(1) specifies that pharmaceutical benefits are to be provided by the Commonwealth in accordance with Part VII of the Act, which details the criteria for determining the forms and administration of listed drugs. Subsection 85(2) empowers the Minister to declare by legislative instrument the drugs and medicinal preparations to which Part VII applies, with certain exceptions. The Minister can further determine the form or forms of a listed drug by reference to strength, type of unit, size of unit, or other factors under subsection 85(3), the manner of administration under subsection 85(5), and a brand of the pharmaceutical item under subsection 85(6). These determinations are crucial as they define what constitutes a pharmaceutical benefit under Part VII of the Act. Under the Act, the Minister has the authority to determine the conditions subject to which payments will be made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners, as outlined in paragraph 98C(1)(b). This power enables the Minister to set the terms and conditions under which pharmaceutical benefits are provided. The legislative instrument PB 20 of 2010 amends PB 119 of 2008, which came into effect on 1 December 2008, and specifies the conditions for payments related to the supply of pharmaceutical benefits. However, an administrative oversight resulted in an incorrect description of the “type of unit” for the drug dabigatran etexilate, which should have been listed as “capsules” instead of “tablets.” This error is corrected by the amending instrument, which substitutes the incorrect reference with the correct one before the commencement of PB 20 of 2010. The amending instrument, numbered PB 32 of 2010, made on 26 March 2010, rectifies the oversight by amending instrument PB 20 of 2010. The amendment specifies that the correct forms for the listed drug dabigatran etexilate are capsules 75 mg (as mesilate), 60 and capsules 110 mg (as mesilate), 60. This correction is intended to take effect before PB 20 of 2010 commences on 1 April 2010, ensuring that the correct pharmaceutical forms are recognised under the Act. The responsible person supplying the drug and Medicare Australia, which administers payments for these pharmaceutical benefits, have been informed of this amendment. In terms of obligations, the Minister’s determinations under the Act bind approved pharmacists and approved medical practitioners in their supply of pharmaceutical benefits. These professionals must adhere to the conditions set out in the legislative instruments to be eligible for Commonwealth payments. Failure to comply with these conditions may result in penalties. While the specific penalties for breaches are not detailed in the Act, non-compliance with legislative instruments governing the PBS could lead to civil or criminal consequences, including fines and other sanctions as provided by law. The Minister's role in ensuring the accuracy and integrity of the legislative instruments is crucial to maintaining the effectiveness of the PBS and ensuring that all parties comply with the stipulated requirements.